share_log

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $145

Benzinga ·  Apr 26 08:49

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $144 to $145.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment